Skip to main content
. 2018 May 4;9(34):23439–23442. doi: 10.18632/oncotarget.25211

Figure 2. Potential paradigm-shifting effect of a cancer stem cell (CSC) inhibitor on tumor chemoresistance.

Figure 2